PROJECT
SUPERVISORS

All supervisors

Project Supervisor

Víctor M. Díaz

Background

I am Head of Research at OneChain Immunotherapeutics, where I lead a team dedicated to advancing innovative cell and gene therapies. I earned my PhD in Biochemistry from the University of Barcelona, followed by two postdoctoral training stays, first as an MSCA fellow at San Raffaele Institute (Milan) on homeobox proteins, and then as a Juan de la Cierva researcher at IMIM-Hospital del Mar (Barcelona), studying cancer mechanisms of protein degradation and stabilization. Afterwards, I became a Lecturer and later an Associate Professor of Biochemistry at Pompeu Fabra University.

See more

In 2020 I joined OneChain, funded by a Torres Quevedo grant from the Spanish State Research Agency (AEI). Since then, I have contributed to four patents on CAR-T therapies, supported EMA and FDA Orphan Drug Designations, and directed preclinical studies leading to the first-in-human CAR-CD1a trial for cortical T-cell Acute Lymphoblastic Leukemia (T-ALL).

See less

Research

We focus on advancing innovative cell and gene therapies with a strong translational orientation. Our work covers the full pipeline, from discovery and preclinical development to product innovation and process engineering, with special expertise in lentiviral vector design and optimization. We develop both autologous and allogeneic CAR-T therapies, having generated candidates against T-ALL, B-ALL, and glioblastoma, as well as an allogeneic platform based on γδ T cells.

See more

A key aspect of our research is integrating mechanistic insights with applied development, ensuring that novel CAR designs translate into clinically meaningful therapies. The lab also contributes to intellectual property generation, regulatory documentation (IND support), and engagement with scientific and clinical stakeholders. Through rigorous experimentation, careful data analysis, and the mentoring of PhD students, we aim to expand the therapeutic potential of CAR-T technology and accelerate its transition to patients.

See less

Publications

Tirado N, Fidyt K, Mansilla A, Vinyoles M, Roca-Ho H, Fernandez-Fuentes N, Guerrero-Murillo M, Falgàs A, Velasco-Hernandez T, Bueno C, Panelli P, Mulens-Arias V, Apostol A, Genescà E, Ribera J, Sánchez-Martínez D, Torrebadell M, Díaz VM, Menéndez P (2025). CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. Journal of Hematology & Oncology, 18(1):69.
https://doi.org/10.1186/s13045-025-01715-0

Menéndez P, Sánchez-Martínez D, Tirado N, Fernández N, Díaz VM (2023). CCR9 targeting moiety for the treatment of CCR9-positive cancer. PCT/EP2024/053734, filed 15 Feb 2023. OneChain Immunotherapeutics, S.L.
https://patentscope.wipo.int/search/en/WO2024170627

Díaz VM, Menéndez P, Sánchez-Martínez D, García Pérez L (2022). Humanized CD1a targeting moiety for the treatment of CD1a-positive cancer. PCT/EP2023/055034, filed 28 Feb 2022. OneChain Immunotherapeutics, S.L.
https://patentscope.wipo.int/search/en/WO2023161530

García León MJ, Fuentes Villarejo P, Alcain Sánchez J, Toribio García ML, García Pérez L, Díaz VM (2022). Method of producing Vδ1+ T cells. PCT/EP2023/050665, filed 12 Jan 2022. OneChain Immunotherapeutics, S.L.
https://patentscope.wipo.int/search/en/WO2023135225

Menéndez P, Velasco T, Romina S, Engel P, Sánchez D, Gutierrez F, Díaz VM (2021). CD22 targeting moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). PCT/EP2021/056262, filed 11 Mar 2021. OneChain Immunotherapeutics, S.L.
https://patentscope.wipo.int/search/en/WO2021180890